544709

- Management explained Q1 FY27 profit moderation due to front-loaded expansion costs and a one-time pan-India marketing push for new AI-led embryology tools (SiD & ERICA). - Reaffirmed FY27 revenue growth guidance of 30% year-on-year, expecting to achieve FY26 EBITDA and PAT levels by year-end. - Expansion plans are on track, with one new IVF hub operational and two more expected within a month, progressing towards 10 new hubs in FY27. - The AI-led embryology tools (SiD & ERICA) have shown an ~8% improvement in first-attempt IVF success rates. - Board approved an additional ₹15 Cr capex for Gaudium Women Hospital in Lucknow, to be funded by internal accruals, with commercialization expected by FY28-29. - The company maintains a debt-light balance sheet with a 0.04 debt-to-equity ratio.

- Gaudium IVF and Women Health Limited submitted a revised Investor Presentation for Q1 FY27 (quarter ended June 30, 2026). - The revision includes disclosure of a one-time marketing cost of Rs. 253.24 lakhs. - Revised Consolidated Adjusted EBITDA: Rs. 532.75 lakhs (27.49% margin). - Revised Standalone Adjusted EBITDA: Rs. 507.75 lakhs (37.12% margin).

- Gaudium IVF and Women Health Limited filed an Investor Presentation for Q1 FY27 financial results for the quarter ended June 30, 2026. - The presentation highlights the company's network of 8 hubs + 28 spokes across 9 states in India. - It also mentions a 62% IVF success rate on the first attempt, improving to 85% with AI initiatives (SID & ERICA).

- Q1 FY27 Consolidated Revenue ₹19.4 Cr vs ₹17.8 Cr (▲9.13% YoY) - EBITDA ₹2.4 Cr vs ₹5.2 Cr (▼52.96% YoY) - PAT ₹1.8 Cr vs ₹3.1 Cr (▼42.27% YoY) - EBITDA Margin 12.51% vs 29.02% (▼1651 bps) - Decline in profitability attributed to strategic investments for FY27 hub rollout and pre-operationalisation costs for future expansion. - Commenced commercial operations at its new IVF Centre/Hub in South Extension, New Delhi. - Board approved 'Gaudium Women Hospital, Lucknow' with an estimated project cost of up to ₹15 crore, marking entry into Uttar Pradesh.

- Q1 FY27 Standalone Revenue ₹13.68 Cr vs ₹12.27 Cr (▲11.44% YoY) - EBITDA ₹2.17 Cr vs ₹4.16 Cr (▼47.69% YoY) - PAT ₹1.66 Cr vs ₹2.35 Cr (▼29.24% YoY) - EBITDA Margin 15.89% vs 33.86% (▼1797bps) - The Board also approved the re-appointment of Ram Rattan & Associates as Internal Auditor for FY2026-27 and appointed M/s. Suresh Nainwal & Company as Secretarial Auditor for 5 years. - The 11th AGM is scheduled for Monday, September 28, 2026.

- Q1 FY27 Consolidated Operating Revenue ₹13.68 Cr vs ₹12.27 Cr (▲11.44% YoY) - EBITDA ₹2.28 Cr vs ₹4.16 Cr (▼45.26% YoY) - PAT ₹1.66 Cr vs ₹2.35 Cr (▼29.24% YoY) - EBITDA Margin 16.63% vs 33.86% (▼1723bps) - Board approved the re-appointment of Ram Rattan & Associates as Internal Auditor for FY2026-27. - Board approved the appointment of M/s. Suresh Nainwal & Company as Secretarial Auditor for 5 years (FY2026-27 to FY2030-31). - The 11th Annual General Meeting (AGM) is scheduled for September 28, 2026, via Video Conferencing/Other Audio-Visual Means.

- Q1 FY27 Consolidated Revenue ₹1,937.66 Lakhs vs ₹1,775.59 Lakhs (▲9.1% YoY) - EBITDA ₹242.41 Lakhs vs ₹515.28 Lakhs (▼53.0% YoY) - PAT ₹177.59 Lakhs vs ₹307.62 Lakhs (▼42.3% YoY) - EBITDA Margin 12.5% vs 29.0% (▼1651 bps) - The Board approved re-appointment of Internal Auditor and appointment of Secretarial Auditor. The 11th AGM is scheduled for September 28, 2026. IPO funds utilization showed no deviation, with remaining debt repayment funds reallocated to General Corporate Purposes within limits.

- Q1 FY27 Consolidated Revenue ₹1,937.66 Lakhs vs ₹1,775.59 Lakhs (▲9.1% YoY) - EBITDA ₹242.41 Lakhs vs ₹515.28 Lakhs (▼53.0% YoY) - PAT ₹177.59 Lakhs vs ₹307.62 Lakhs (▼42.3% YoY) - EBITDA Margin 12.5% vs 29.0% (▼1650bps)

- Concall Schedule - Concall Date: August 14, 2026 - Concall Time: 02:00 P.M. IST

New Filing detected. See link for details.

- Gaudium IVF and Women Health Limited announced the launch of AI Powered Signature Labs and the commencement of its planned 19-centre expansion on July 16, 2026. - The first milestone in this expansion is a new centre in South Delhi, featuring AI-assisted embryology and standardized Signature Lab model.

- Gaudium IVF and Women Health Limited announced the commencement of commercial operations for its new IVF Centre/Hub at South Extension, New Delhi. - The new centre will be operational from July 16, 2026. - It will provide fertility and reproductive healthcare services, including In Vitro Fertilization (IVF). - This expansion is in line with the objects mentioned in the Company's Initial Public Offer.

- Trading window for designated persons and their immediate relatives closed from July 01, 2026. - Closure is for the upcoming unaudited financial results for the quarter ending June 30, 2026. - The Board meeting date for approving the financial results will be intimated separately.

- Corrigendum filed to correct inadvertent regrouping and typographical errors in the comparative consolidated financial figures for the year ended March 31, 2025. This includes minor adjustments to assets, liabilities, and tax expenses. - These corrections do not impact the current year's (March 31, 2026) financial results, PAT, Net Worth, or the auditor's report. - Standalone financial results for all periods were correctly reported.

- Board approved setting up "Gaudium Women Hospital, Lucknow" through a 30-year land lease arrangement. - Estimated project cost is up to ₹15 Crores towards development and operationalization. - The company will pay 10% of net revenue to the landowner and place a security deposit of ₹3 Crores.

- Analyst/Institutional Investor Meet scheduled by Gaudium IVF and Women Health Limited. - Date of Meet: Friday, June 12, 2026 - Time: 11:00 AM to 12:00 PM - With: InsightX Conference, organized by Choice Broking - Note: Discussions will be based on publicly available information; no UPSI will be shared.

Gaudium IVF and Women Health Limited announced the availability of the audio recording of its Earnings Call on the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026. The recording, held on May 29, 2026, is accessible on the company's website.

Consolidated Revenue ₹30.35 Cr vs ₹26.92 Cr (▲12.74% YoY), EBITDA ₹12.17 Cr vs ₹8.72 Cr (▲39.56% YoY), PAT ₹8.36 Cr vs ₹6.45 Cr (▲29.46% YoY). EBITDA Margin 40.10% vs 32.39% (▲771bps).

Consolidated Revenue ₹30.35Cr vs ₹26.92Cr (▲12.73% YoY), EBITDA ₹12.17Cr vs ₹8.72Cr (▲39.56% YoY), PAT ₹8.36Cr vs ₹6.46Cr (▲29.46% YoY). EBITDA Margin 40.11% vs 32.39% (▲772bps).

Gaudium IVF and Women Health Limited reported strong financial performance for the quarter ended March 31, 2026. Consolidated Revenue stood at ₹3,035.11 Lakhs compared to ₹2,692.43 Lakhs (▲12.73% YoY). EBITDA significantly increased to ₹1,234.94 Lakhs from ₹895.61 Lakhs (▲37.88% YoY). Net Profit (PAT) grew to ₹835.74 Lakhs from ₹645.56 Lakhs (▲29.46% YoY). EBITDA Margin expanded from 33.26% to 40.69% (▲743bps). The company also completed its IPO during the year.